AGMB PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

AGMB ▼ -6.91% at T+20d

NEUTRAL call ✗ call lost -6.91% · α vs SPY -17.57% · entry $11.87 → $11.05

Next anchor: T+60d in 10d

Currently $9.61 · -19.04% from $11.87 entry

Entry anchored
Mar 25, 03:58 PM ET
via Databento tick

T+1d

-8.59%

call -8.59% · α -6.91%

$10.85

settled 3mo ago

T+5d

-9.69%

call -9.69% · α -11.32%

$10.72

settled 2mo ago

T+20d

-6.91%

call -6.91% · α -17.57%

$11.05

settled 7w ago

T+60d

—

call — · α —

—

in 10d

Price Chart

Loading chart...

Executive Summary

AgomAb Therapeutics announced the issuance of a U.S. patent (No. 12,577,230) covering the composition of matter for its investigational inhaled drug AGMB-447, providing IP protection through at least 2041. The drug is currently in a Phase 1b trial for idiopathic pulmonary fibrosis (IPF), with patient cohort results expected later in 2026.

Actionable Insight

Monitor upcoming Phase 1b IPF patient data readout later in 2026, which will be a key catalyst for valuation. The patent strengthens IP position but does not alter near-term financials.

Key Facts

U.S. Patent No. 12,577,230 granted for AGMB-447, covering composition of matter.
Patent provides U.S. IP protection through at least 2041, excluding potential extensions.
AGMB-447 is an inhaled, lung-restricted ALK5 inhibitor in Phase 1b development for IPF.
Positive healthy subject data previously reported; IPF patient data expected later in 2026.
AGMB-447 is not approved; efficacy and safety not yet established.

Financial Impact

No immediate financial impact disclosed; long-term value depends on clinical success and commercialization.

ip_valuer_d_pipelinemarket_exclusivity

Risk Factors

Clinical development risk: AGMB-447 may fail to demonstrate efficacy or safety in IPF patients.
Forward-looking statements are subject to uncertainties in drug development and IP enforceability.

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3262841

4 reports for AGMB

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for AGMB — sortable, filterable
	Type				Now
May 27, 2026 17d ago	Press Release NEUTRAL ★ 2/10	$11.67 $12.00	▲ +2.83%	▲ +2.36%	$9.61 (−17.65%)
May 14, 2026 4w ago	Press Release NEUTRAL ★ 2/10	$11.04 $10.94	▼ −0.91%	▼ −0.19%	$9.61 (−12.95%)
Apr 24, 2026 7w ago	6-K BULLISH ★ 8/10	$11.32 $12.11	▲ +6.98%	▲ +6.58%	$9.61 (−15.11%)
Mar 26, 2026 11w ago	Press Release NEUTRAL ★ 5/10	$11.87 $10.72	▼ −9.69%	▼ −11.32%	$9.61 (−19.04%)

US Market Status

Market Closed — Opens Mon (49h 32m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access